{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:28:47Z","timestamp":1767176927242,"version":"build-2238731810"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICI) and Tyrosine kinase inhibitors (TKI) are effective for several types of cancers, but they can have several cardiotoxicity sides effects. We present a case of TKI-ICI toxicity resulting in multiorgan inflammatory syndrome with myocarditis and thrombotic STEMI that were successfully treated with high-dose steroids and PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Seventy-two year-old man patient treated with on pembrolizumab 200\u00a0mg IV every 3\u00a0weeks and Axitinib 5\u00a0mg PO q12h for the past 5\u00a0months complained of acute shortness of breath, altered mental status, and chronic diarrhea. Coronary angiography demonstrated a thrombotic lesion in the right coronary artery (RCA) that was treated successfully with percutaneous coronary intervention (PCI). Despite PCI he continued to complain of shortness of breath further workup with Cardiac MRI (CMR) was obtained showed an ejection fraction of 38%, small pericardial effusion, and delayed gadolinium enhancement (DGE) in the inferior wall suggestive of myocarditis. An empirical trial of high-dose steroids improved all patient symptoms and ejection fraction; therefore, the chemotherapy regimen was changed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case report highlights the potential vasculogenic effects of Axitinib and immune-related myocarditis of pembrolizumab. Cardiologists and oncologists should be vigilant for the cardiotoxic effects of Axitinib and pembrolizumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40959-022-00152-z","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T03:02:31Z","timestamp":1701831751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The toxic tango: TKI and ICI cardiotoxicities"],"prefix":"10.1186","volume":"9","author":[{"given":"Juan","family":"Del Cid Fratti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijayasree","family":"Paleru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhuri","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"issue":"3","key":"152_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/op.21.00419","volume":"18","author":"J Tran","year":"2022","unstructured":"Tran J, Ornstein MC. Clinical Review on the Management of Metastatic Renal Cell Carcinoma. JCO Oncol Pract. 2022;18(3):187\u201396. https:\/\/doi.org\/10.1200\/op.21.00419.","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"152_CR2","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/jaha.119.013757","volume":"9","author":"N Palaskas","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020;9(2):e013757. https:\/\/doi.org\/10.1161\/jaha.119.013757.","journal-title":"J Am Heart Assoc."},{"issue":"6","key":"152_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","volume":"12","author":"RM Touyz","year":"2018","unstructured":"Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018;12(6):409\u201325. https:\/\/doi.org\/10.1016\/j.jash.2018.03.008.","journal-title":"J Am Soc Hypertens"},{"issue":"4","key":"152_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/1055-9965.epi-12-1356","volume":"22","author":"JS de Moor","year":"2013","unstructured":"de Moor JS, Mariotto AB, Parry C, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22(4):561\u201370. https:\/\/doi.org\/10.1158\/1055-9965.epi-12-1356.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"152_CR5","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/s1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack ER, Souli\u00e8res D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(12):1563\u201373. https:\/\/doi.org\/10.1016\/s1470-2045(20)30436-8.","journal-title":"Lancet Oncol"},{"issue":"12","key":"152_CR6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923.","journal-title":"JAMA Oncol"},{"issue":"21","key":"152_CR7","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1161\/circulationaha.117.029626","volume":"136","author":"G Varricchi","year":"2017","unstructured":"Varricchi G, Galdiero MR, Tocchetti CG. Cardiac Toxicity of Immune Checkpoint Inhibitors: Cardio-Oncology Meets Immunology. Circulation. 2017;136(21):1989\u201392. https:\/\/doi.org\/10.1161\/circulationaha.117.029626.","journal-title":"Circulation"},{"issue":"2","key":"152_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/circulationaha.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation. 2019;140(2):80\u201391. https:\/\/doi.org\/10.1161\/circulationaha.118.034497.","journal-title":"Circulation"},{"issue":"24","key":"152_CR9","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018;72(24):3158\u201376. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.072.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"152_CR10","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/jco.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714\u201368. https:\/\/doi.org\/10.1200\/jco.2017.77.6385.","journal-title":"J Clin Oncol"},{"issue":"1","key":"152_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/cji.0000000000000190","volume":"41","author":"A Tajmir-Riahi","year":"2018","unstructured":"Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L. Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy. J Immunother. 2018;41(1):35\u20138. https:\/\/doi.org\/10.1097\/cji.0000000000000190.","journal-title":"J Immunother"}],"updated-by":[{"DOI":"10.1186\/s40959-024-00200-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000}}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-022-00152-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-022-00152-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-022-00152-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T03:06:19Z","timestamp":1705547179000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-022-00152-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["152"],"URL":"https:\/\/doi.org\/10.1186\/s40959-022-00152-z","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"19 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40959-024-00200-w","URL":"https:\/\/doi.org\/10.1186\/s40959-024-00200-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None patient data is de-identified and no further contact with patient was performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We consent this journal for publication. This manuscript has not been shared with other institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None related to the case.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}